AroCell Q2: Good cost control, somewhat lower sales - Redeye

Redeye returns with a more detailed take on the Q2 report and notes lower costs than expected and anticipate a continuous upswing of TUBEX sales while lowering FY 2022E sales somewhat. We reiterate our fair value range.

Länk till analysen i sin helhet: https://www.redeye.se/research/851932/arocell-q2-2022-good-cost-control-somewhat-lower-sales?utm_source=finwire&utm_medium=RSS